NCI Cancer Bulletin: A Trusted Source for Cancer Research NewsNCI Cancer Bulletin: A Trusted Source for Cancer Research News
September 20, 2005 • Volume 2 / Number 36 E-Mail This Document  |  Download PDF  |  Bulletin Archive/Search  |  Subscribe

NCI Cancer Bulletin Archive

Page Options

  • Print This Page
  • Print This Document
  • View Entire Document
  • Email This Document
  • View/Print PDF

The information and links on this page are no longer being updated and are provided for reference purposes only.

Featured Clinical TrialFeatured Clinical Trial

Chemotherapy for Advanced or Recurrent Endometrial Cancer

Name of the Trial
Phase III Randomized Study of Doxorubicin, Cisplatin, Paclitaxel, and Filgrastim (G-CSF) versus Carboplatin and Paclitaxel in Patients with Stage III or IV or Recurrent Endometrial Cancer (GOG-0209). See the protocol summary at http://cancer.gov/clinicaltrials/GOG-0209.

Dr. David Scott Miller Principal Investigator
Dr. David Scott Miller, Gynecologic Oncology Group

Why Is This Trial Important?
Endometrial cancer is cancer that arises from the lining of the uterus (the endometrium). It is the most common form of gynecologic cancer. Although endometrial cancer is curable in its early stages, advanced disease is often fatal.

Currently, there is no standard treatment for endometrial cancer that has spread beyond the uterus or recurred. Doctors treating patients with such cancers usually rely on one of two chemotherapy combinations: treatment with the drugs doxorubicin, cisplatin, and paclitaxel plus the biologic agent filgrastim (TAP) or with a combination of carboplatin and paclitaxel (TC).

In this trial, researchers will compare these two chemotherapy combinations in women with advanced or recurrent endometrial cancer to determine which combination will help patients survive longer. Additionally, the researchers will assess the patients' quality of life and examine the side effects of each combination.

"This is the most recent in a series of trials evaluating new drug treatments for endometrial cancer," said Dr. Miller. "In our previous studies, TAP emerged as the leading treatment choice. Many oncologists, however, use the TC combination, which is also used to treat ovarian cancer.

"This study is designed to set the standard of care for women with advanced endometrial cancer by comparing these two leading chemotherapy combinations," Dr. Miller said.

Who Can Join This Trial?
Researchers seek to enroll 900 patients aged 18 or over with confirmed stage III or stage IV or recurrent endometrial cancer who have not previously undergone chemotherapy. See the list of eligibility criteria at http://cancer.gov/clinicaltrials/GOG-0209.

Where Is This Trial Taking Place?
Multiple study sites in the United States are recruiting patients for this trial. See the list of study sites at http://cancer.gov/clinicaltrials/GOG-0209.

Contact Information
See the list of study contacts at http://cancer.gov/clinicaltrials/GOG-0209 or call the NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). The call is toll free and completely confidential.


An archive of "Featured Clinical Trial" columns is available at http://cancer.gov/clinicaltrials/ft-all-featured-trials.